PTK7在口腔鳞癌中的表达分析及其生物学功能研究

doi:10.13591/j.cnki.kqyx.2024.04.006

摘要/Abstract

摘要：

目的探讨PTK7在口腔鳞癌(oral squamous cell carcinoma, OSCC)中的表达水平、潜在的生物学功能及其临床意义。方法采用实时荧光PCR(quantitive real-time polymerase chain reaction, qPCR)和Western blot检测PTK7在OSCC细胞系和口腔鳞癌组织标本中的表达情况,利用siRNA干扰技术下调PTK7在HN6和Cal27细胞系中的表达,通过CCK-8实验、平板克隆实验、细胞划痕实验及Transwell实验检测PTK7下调后其对OSCC细胞系增殖、迁移、侵袭的影响;同时采用免疫组织化学染色法检测75例口腔鳞癌组织中PTK7蛋白的表达水平,分析其相关的临床意义。结果 qPCR及Western blot结果显示PTK7基因及其编码蛋白在口腔鳞癌细胞系HN6和Cal27中高表达,并在6例新鲜口腔鳞癌标本中的表达高于其配对的癌旁正常组织;下调PTK7的表达可抑制OSCC细胞增殖、迁移和侵袭功能;在75例口腔鳞癌组织中,PTK7的表达水平与OSCC患者的发病年龄、吸烟情况、病理分化程度等相关,其差异有统计学意义(P<0.05)。Kaplan-Meier生存分析发现,高表达PTK7的OSCC患者的预后较差。结论 PTK7是口腔鳞癌发生发展过程的潜在癌基因,其表达水平影响OSCC细胞的生物学功能,临床上可根据PTK7表达水平了解口腔鳞癌的特性,PTK7可作为口腔鳞癌预后判定的独立指标。

关键词: 口腔鳞癌, 蛋白酪氨酸激酶7, 增殖, 迁移, 侵袭

Abstract:

Objective To explore the expression level of PTK7 in OSCC, and study its potential biological function and clinical significance. Methods qPCR and Western blot were performed to detect the expression of PTK7 in OSCC cell lines and OSCC tissue specimens. siRNA interference technology was used to down-regulate the expression of PTK7 in HN6 and Cal27 cell lines. The effects of down-regulated PTK7 on the proliferation, migration, invasion of OSCC cells were detected by CCK-8 assay, plate cloning assay, cell scratch assay, Transwell assay. Immunohistochemistry was used to detect the expression level of PTK7 protein in 75 cases of OSCC tissue. Results The results of qPCR and Western blot showed that PTK7 gene and its coding protein were highly expressed in OSCC lines HN6 and Cal27, and the expression of PTK7 gene and its coding protein was higher in 6 fresh OSCC samples than in their paired adjacent normal tissues. Down-regulating the expression of PTK7 could inhibit the proliferation, migration and invasion of OSCC cells. In the 75 OSCC specimens, the expression level of PTK7 was significantly associated with the patients’ age, smoking and differentiation degree (P<0.05). Kaplan Meier survival analysis found that OSCC patients with high expression of PTK7 had poorer prognosis. Conclusion PTK7 is a potential oncogene in the occurrence and development of OSCC, and its expression level affects the biological function of OSCC cells. The characteristics of OSCC can be understood clinically according to the expression level of PTK7, and PTK7 can be used as an independent prognostic indicator for OSCC.

Key words: oral squamous cell carcinoma, protein tyrosine kinase 7, proliferation, migration, invasion

中图分类号:

R782
R739.8

孙昕奕, 潘玥彤, 陆欣悦, 吕中静, 袁健, 李家锋, 石欢. PTK7在口腔鳞癌中的表达分析及其生物学功能研究[J]. 口腔医学, 2024, 44(4): 268-275.

SUN Xinyi, PAN Yuetong, LU Xinyue, LYU Zhongjing, YUAN Jian, LI Jiafeng, SHI Huan. Analysis of PTK7 expression in oral squamous cell carcinoma and its biological function[J]. Stomatology, 2024, 44(4): 268-275.

图/表 11

图1

图2

图3

图4

图5

图6

图7

图8

图9

表1

表2

参考文献 24

[1]	陈新, 徐文华, 周健, 等. 口腔鳞状细胞癌现状[J]. 口腔医学, 2017, 37(5):462-465.
[2]	Prgomet D, Bišof V, Prstačić R, et al. The multidisciplinary team (mdt) in the treatment of head and neck cancer-a single-institution experience[J]. Acta Clin Croat, 2022, 61(Suppl 4):77-87. doi: 10.20471/acc.2022.61.s4.10 pmid: 37250663
[3]	Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019, 144(8):1941-1953. doi: 10.1002/ijc.31937 pmid: 30350310
[4]	Jiang W, He J, Lv BH, et al. PTK7 expression is associated with lymph node metastasis, ALK and EGFR mutations in lung adenocarcinomas[J]. Histol Histopathol, 2020, 35(5):489-495. doi: 10.14670/HH-18-183 pmid: 31701509
[5]	Zou RC, Liang Y, Li LL, et al. Bioinformatics analysis identifies protein tyrosine kinase 7 (PTK7) as a potential prognostic and therapeutic biomarker in stages Ⅰ to Ⅳ hepatocellular carcinoma[J]. Med Sci Monit, 2019, 25:8618-8627. doi: 10.12659/MSM.917142
[6]	Chen S, Wang Y, Su YN, et al. miR-205-5p/PTK7 axis is involved in the proliferation, migration and invasion of colorectal cancer cells[J]. Mol Med Rep, 2018, 17(5):6253-6260.
[7]	Duan F, Tang J, Kong FL, et al. Identification of PTK7 as a promising therapeutic target for thyroid cancer[J]. Eur Rev Med Pharmacol Sci, 2020, 24(12):6809-6817.
[8]	Raivola J, Dini A, Karvonen H, et al. Multiomics characterization implicates PTK7 in ovarian cancer EMT and cell plasticity and offers strategies for therapeutic intervention[J]. Cell Death Dis, 2022, 13(8):714. doi: 10.1038/s41419-022-05161-5 pmid: 35977930
[9]	Cui NP, Qiao S, Jiang S, et al. Protein tyrosine kinase 7 regulates EGFR/akt signaling pathway and correlates with malignant progression in triple-negative breast cancer[J]. Front Oncol, 2021, 11:699889. doi: 10.3389/fonc.2021.699889
[10]	Sun JJ, Li HL, Guo SJ, et al. The increased PTK7 expression is a malignant factor in cervical cancer[J]. Dis Markers, 2019, 2019:5380197.
[11]	Dong YC, Chen X, Li HZ, et al. PTK7 is a molecular marker for metastasis, TNM stage, and prognosis in oral tongue squamous cell carcinoma[J]. Pol J Pathol, 2017, 68(1):49-54. doi: 29900 pmid: 28547980
[12]	Golubkov VS, Strongin AY. Insights into ectodomain shedding and processing of protein-tyrosine pseudokinase 7 (PTK7)[J]. J Biol Chem, 2012, 287(50):42009-42018. doi: 10.1074/jbc.M112.371153 pmid: 23095747
[13]	Jin XY, Huang T, Ma CH, et al. Protein tyrosine kinase 7-knockdown inhibits oral squamous cell carcinoma cell viability, proliferation, migration and invasion via downregulating dishevelled segment polarity protein 3 expression[J]. Exp Ther Med, 2021, 22(6):1372. doi: 10.3892/etm
[14]	Kimura Y, Yoshizawa K, Hotta-Osada A, et al. High expression of protein tyrosine kinase 7 in oral squamous cell carcinoma: Clinicopathological correlation and prognosis relevance[J]. Clin Exp Dent Res, 2022, 8(2):506-512. doi: 10.1002/cre2.553 pmid: 35257502
[15]	Lv ZJ, Cong R, Li JF, et al. PTHLH predicts the prognosis of patients with oral leukoplakia[J]. Onco Targets Ther, 2020, 13:10013-10023. doi: 10.2147/OTT.S261124
[16]	Patni AP, Harishankar MK, Joseph JP, et al. Comprehending the crosstalk between Notch, Wnt and Hedgehog signaling pathways in oral squamous cell carcinoma-clinical implications[J]. Cell Oncol, 2021, 44(3):473-494. doi: 10.1007/s13402-021-00591-3
[17]	Lindemann A, Takahashi H, Patel AA, et al. Targeting the DNA damage response in OSCC with TP53 mutations[J]. J Dent Res, 2018, 97(6):635-644. doi: 10.1177/0022034518759068 pmid: 29489434
[18]	Gröbe A, Hanken H, Kluwe L, et al. Immunohistochemical analysis of p16 expression, HPV infection and its prognostic utility in oral squamous cell carcinoma[J]. J Oral Pathol Med, 2013, 42(9):676-681. doi: 10.1111/jop.12086 pmid: 23721566
[19]	Cuevas Gonzalez JC, Gaitan Cepeda LA, Borges Yanez SA, et al. p53 and p16 in oral epithelial dysplasia and oral squamous cell carcinoma: A study of 208 cases[J]. Indian J Pathol Microbiol, 2016, 59(2):153-158. doi: 10.4103/0377-4929.182037
[20]	Chai AWY, Lim KP, Cheong SC. Translational genomics and recent advances in oral squamous cell carcinoma[J]. Semin Cancer Biol, 2020, 61:71-83. doi: S1044-579X(19)30260-3 pmid: 31542510
[21]	Murphy JM, Zhang QW, Young SN, et al. A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties[J]. Biochem J, 2014, 457(2):323-334. doi: 10.1042/BJ20131174 pmid: 24107129
[22]	Damelin M, Bankovich A, Bernstein J, et al. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions[J]. Sci Transl Med, 2017, 9(372):eaag2611. doi: 10.1126/scitranslmed.aag2611
[23]	Golubkov VS, Strongin AY. Downstream signaling and genome-wide regulatory effects of PTK7 pseudokinase and its proteolytic fragments in cancer cells[J]. Cell Commun Signal, 2014, 12:15. doi: 10.1186/1478-811X-12-15 pmid: 24618420
[24]	Jin J, Ryu HS, Lee KB, et al. High expression of protein tyrosine kinase 7 significantly associates with invasiveness and poor prognosis in intrahepatic cholangiocarcinoma[J]. PLoS One, 2014, 9(2):e90247. doi: 10.1371/journal.pone.0090247

特征	样本含量n(%)	PTK7表达量	P
性别			0.052
男	45(60)	2.282±0.708
女	30(40)	1.947±0.743
年龄/岁			0.005
<60	27(36)	1.832±0.720
≥60	48(64)	2.326±0.691
吸烟			0.003
是	24(32)	2.504±0.659
否	51(68)	1.981±0.717
饮酒			0.628
是	24(32)	2.088±0.814
否	51(68)	2.177±0.704
淋巴结转移			0.590
是	21(28)	2.222±0.680
否	54(72)	2.119±0.762
分化程度			0.000
低分化	27(36)	2.563±0.624
高分化	48(64)	1.915±0.696

预后因素	样本含量n(%)	HR	95%CI	P
性别		1.351	0.599~3.264	0.503
男	45(60)
女	30(40)
年龄/岁		1.925	0.794~4.667	0.148
<60	27(36)
≥60	48(64)
吸烟		3.538	1.156~10.830	0.027
是	24(32)
否	51(68)
饮酒		0.385	0.144~1.034	0.058
是	24(32)
否	51(68)
淋巴结转移		4.076	1.565~10.619	0.004
是	21(28)
否	54(72)
分化程度		1.636	0.777~3.446	0.195
低分化	27(36)
高分化	48(64)
PTK7表达		0.331	0.156~0.702	0.004
低表达	37(49.3)
高表达	38(50.7)